Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline

Insider Monkey
2025.11.29 18:32

Mizuho increased its price target for Gilead Sciences (GILD) from $131 to $140, maintaining an Outperform rating due to a stronger Biktarvy timeline, with market exclusivity now expected until 2036. This positive outlook is tempered by the failure of Gilead's Trodelvy in a Phase 3 trial for metastatic breast cancer, though potential in the pre-exposure prophylaxis market for Yeztugo is noted.

Source: Insider Monkey The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.